<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium phenylacetate and sodium benzoate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium phenylacetate and sodium benzoate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium phenylacetate and sodium benzoate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10084" href="/d/html/10084.html" rel="external">see "Sodium phenylacetate and sodium benzoate: Drug information"</a> and <a class="drug drug_patient" data-topicid="12123" href="/d/html/12123.html" rel="external">see "Sodium phenylacetate and sodium benzoate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F221922"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ammonul</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062250"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Ammonium Detoxicant</span>;</li>
<li>
<span class="list-set-name">Hyperammonemia Agent</span>;</li>
<li>
<span class="list-set-name">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462592"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Initiate therapy as soon as urea cycle disorder is suspected to reduce risk of irreversible neurological sequelae from hyperammonemia/encephalopathy. Sodium phenylacetate and sodium benzoate should be used.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56052b19-ffc3-4a10-b5a1-c68dc1453a58">Hyperammonemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, acute (urea cycle disorders [UCD]): Note:</b> Use in conjunction with other therapies depending on the specific UCD, including arginine (essential component for most UCDs), caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies as indicated. Antiemetics may be used to prevent or treat infusion-associated nausea and vomiting (BIMDG 2017; Enns 2007; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Ammonul:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i> IV: 2.5 mL/kg (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg) administered over 90 to 120 minutes. <b>Note:</b> Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> Continuous IV infusion: 2.5 mL/kg administered as a maintenance infusion over 24 hours (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg per 24 hours); continue until patient no longer has hyperammonemia and oral therapy can be tolerated.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F221929"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Initiate therapy as soon as urea cycle disorder is suspected to reduce risk of irreversible neurological sequelae from hyperammonemia/encephalopathy. Sodium phenylacetate and sodium benzoate should be used. Dosing is based on weight (mL/kg) and body surface area (mL/<b>m<sup>2</sup></b>) depending on patient weight; use caution to ensure appropriate dosing units.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56052b19-ffc3-4a10-b5a1-c68dc1453a58">Hyperammonemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, acute (urea cycle disorders [UCD]): Note:</b> Use in conjunction with other therapies depending on the specific UCD, including arginine (essential component for most UCDs), caloric supplementation, dietary protein restriction, hemodialysis and other ammonia lowering therapies. Antiemetics may be used to prevent or treat infusion-associated nausea and vomiting (BIMDG 2017; Enns 2007; Häberle 2019; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤20 kg: Ammonul:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i> IV: 2.5 mL/kg (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg) administered over 90 to 120 minutes. <b>Note:</b> Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i>Continuous IV infusion: 2.5 mL/kg administered as a maintenance infusion over 24 hours (provides sodium phenylacetate 250 mg/kg and sodium benzoate 250 mg/kg per 24 hours); continue until patient no longer has hyperammonemia and oral therapy can be tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &gt;20 kg: Ammonul:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose</i>: IV: 55 mL/<b>m<sup>2</sup></b> (provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup>) administered over 90 to 120 minutes. <b>Note:</b> Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i> Continuous IV infusion: 55 mL/<b>m<sup>2</sup></b> administered as a maintenance infusion over 24 hours (provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup> per 24 hours); continue until patient no longer has hyperammonemia and oral therapy can be tolerated.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160181"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, the drug metabolites and ammonia are excreted by the kidneys. Use with caution; monitor closely.</p></div>
<div class="block dohp drugH1Div" id="F51160182"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution, metabolism of sodium phenylacetate/sodium benzoate may be impaired in liver impairment.</p></div>
<div class="block doa drugH1Div" id="F221923"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10084" href="/d/html/10084.html" rel="external">see "Sodium phenylacetate and sodium benzoate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Initiate therapy as soon as urea cycle disorder is suspected to reduce risk of irreversible neurological sequelae from hyperammonemia/encephalopathy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56052b19-ffc3-4a10-b5a1-c68dc1453a58">Hyperammonemia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, acute (in patients with known or suspected urea cycle disorders) (adjunctive therapy): </b>
<b>Note:</b> Use in conjunction with other therapies depending on the specific urea cycle disorder, including arginine (essential component for most urea cycle disorders), caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies (Enns 2007). Antiemetics may be needed to prevent or treat infusion-associated nausea and vomiting (Enns 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose</b>: <b>IV:</b> 55 mL/<b>m<sup>2 </sup></b>(provides sodium phenylacetate 5.5 g/m<sup>2</sup> and sodium benzoate 5.5 g/m<sup>2</sup>) administered over 90 to 120 minutes. <b>Note</b>: Repeat loading doses are not recommended due to neurotoxicity associated with prolonged plasma levels of phenylacetate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose:</b>
<b>IV:</b> 55 mL/<b>m<sup>2</sup></b> administered as a maintenance infusion over 24 hours until patient no longer has hyperammonemia and oral therapy can be tolerated.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990858"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, since the conjugates formed from treatment (phenylacetylglutamine and hippurate) are excreted by the kidneys, adequate kidney function is needed (Häberle 2012; Husson 2016).</p></div>
<div class="block doha drugH1Div" id="F50988137"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution as metabolic conjugation of sodium benzoate and sodium phenylacetate takes place in the liver and kidneys.</p></div>
<div class="block adr drugH1Div" id="F221897"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics treated for on-label and off-label indications.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Infection: Infection (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (&lt;3%), cardiogenic shock (&lt;3%), cardiomyopathy (&lt;3%), chest pain (&lt;3%), edema (&lt;3%), flushing (&lt;3%), heart failure (&lt;3%), hypertension (&lt;3%), hypotension (4%; more common in neonates), low cardiac output (&lt;3%), myocardial rupture (atria) (&lt;3%), pericardial effusion (&lt;3%), thrombosis (&lt;3%), venous thrombosis (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;3%), pruritus (&lt;3%), skin blister (&lt;3%), skin rash (&lt;3%), urticaria (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (3%), alkalosis (&lt;3%), dehydration (&lt;3%), fluid retention (&lt;3%), hyperammonemia (5%), hyperglycemia (7%), hyperkalemia (&lt;3%), hypernatremia (&lt;3%), hypervolemia (&lt;3%), hypocalcemia (3%), hypoglycemia (&lt;3%), hypokalemia (7%), increased serum pH (&lt;3%), metabolic acidosis (4%), respiratory acidosis (&lt;3%), respiratory alkalosis (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;3%), cholestasis (&lt;3%), diarrhea (3%), gastrointestinal hemorrhage (&lt;3%), nausea (3%), vomiting (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria (&lt;3%), urinary retention (&lt;3%), urinary tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4%), disorder of hemostatic components of blood (&lt;3%), disseminated intravascular coagulation (3%), hemangioma (&lt;3%), hemorrhage (&lt;3%), pancytopenia (&lt;3%), thrombocytopenia (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic artery stenosis (&lt;3%), hepatic failure (&lt;3%), hepatotoxicity (&lt;3%), jaundice (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (&lt;3%), septic shock (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Absent reflexes (&lt;3%), acute psychosis (&lt;3%), aggressive behavior (&lt;3%), agitation (3%), asthenia (&lt;3%), ataxia (&lt;3%), brain edema (5%), cerebral atrophy (&lt;3%), cerebral hemorrhage (&lt;3%), cerebral herniation (&lt;3%), cerebral infarction (&lt;3%), clonus (&lt;3%), coma (3%), confusion (&lt;3%), decreased mental acuity (6%), encephalopathy (&lt;3%), hallucination (&lt;3%), impaired consciousness (&lt;3%), increased intracranial pressure (&lt;3%), paralysis (nerve) (&lt;3%), seizure (6%), subdural hematoma (&lt;3%), tremor (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tetany (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney failure (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Aspiration pneumonia (&lt;3%), dyspnea (&lt;3%), hypercapnia (&lt;3%), hyperventilation (&lt;3%), Kussmaul respiration (&lt;3%), pneumothorax (&lt;3%), pulmonary edema (&lt;3%), pulmonary hemorrhage (&lt;3%), respiratory distress (3%, including acute respiratory distress), respiratory failure (&lt;3%), tachypnea (&lt;3%), variations in blood CO<sub>2</sub> concentration (&lt;3%, including partial pressure CO<sub>2</sub>)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5%), multi-organ failure (&lt;3%)</p></div>
<div class="block coi drugH1Div" id="F221911"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F221895"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Infuse via central line ONLY; peripheral administration may cause burning. May be an irritant with vesicant-like properties; avoid extravasation. Monitor infusion site closely during administration. If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Use with caution, if at all, in patients at risk for fluid overload (eg, heart failure, severe renal impairment) or sodium retention edema; contains a significant amount of sodium. Discontinue use if patient experiences clinically significant fluid overload.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Nausea and vomiting may occur; premedication with antiemetics may be administered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: May occur; monitor plasma potassium and initiate appropriate treatment as necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic acidosis/hyperventilation: Use may cause hyperventilation and metabolic acidosis; phenylacetate and benzoate are structurally similar to salicylate, therefore, adverse effects typically associated with salicylate overdose may occur with sodium phenylacetate/sodium benzoate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Phenylacetate may result in neurotoxicity (fatigue, lightheadedness, somnolence); symptoms were observed upon initiation of treatment and were reversible with discontinuation. Avoid repeat loading doses due to potential for neurotoxicity associated with prolonged plasma levels of phenylacetate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; metabolism of sodium phenylacetate/sodium benzoate may be impaired.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; excretion of drug metabolites (phenylacetylglutamine and hippurate) and ammonia may be reduced since primarily excreted by the kidneys; use may also predispose to fluid overload.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium benzoate: Contains sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878636"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Enhanced potassium excretion may occur with treatment of hyperammonemia; monitor serum potassium concentration closely. Repeat loading doses of drug are not indicated due to prolonged plasma levels noted in pharmacokinetic studies. Maintain caloric intake of &gt;80 cal/kg/day.</p></div>
<div class="block foc drugH1Div" id="F221905"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [concentrate]:</p>
<p style="text-indent:-2em;margin-left:4em;">Ammonul: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Sodium phenylacetate 100 mg and sodium benzoate 100 mg per 1 mL (50 mL)</p></div>
<div class="block geq drugH1Div" id="F221891"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323874"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ammonul Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-10% (per mL): $1,095.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sod Benz-Sod Phenylacet Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10-10% (per mL): $120.00 - $876.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613869"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Must dilute prior to administration; may administer in combination with arginine. Infuse via central line ONLY (administration via peripheral line may cause burns). Infuse loading dose over 90 to 120 minutes; maintenance dose is a continuous infusion infused over 24 hours. Antiemetics may be needed to decrease nausea during infusion. May be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation (may cause necrosis). If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary).</p></div>
<div class="block adm drugH1Div" id="F221908"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Must be diluted with 10% dextrose (D10W) prior to administration. Infuse via central line ONLY (administration via peripheral line may cause burning). If extravasation is suspected discontinue infusion and resume at a different infusion site (if necessary). Infuse loading dose over 90 to 120 minutes, followed by a maintenance dose administered over 24 hours. May be an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and monitor site during infusion; avoid extravasation (may cause necrosis).</p></div>
<div class="block sts drugH1Div" id="F221918"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Following dilution, solution for infusion may be stored at room temperature for up to 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53568910"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct treatment of acute hyperammonemia and encephalopathy in patients with urea cycle disorders (FDA approved in all ages).</p></div>
<div class="block cyt drugH1Div" id="F13300065"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223020"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F221915"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Contains 30.5 mg of sodium per mL of undiluted product. Caloric supplementation and dietary protein restriction should be part of treatment. Caloric intake of &gt;80 cal/kg/day should be attempted.</p></div>
<div class="block pri drugH1Div" id="F221914"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Phenylacetate and benzoate can be detected in umbilical cord and newborn blood following sodium phenylacetate/sodium benzoate infusion during labor (Wilnai 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the Sodium Benzoate monograph for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53568905"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Neurologic status, Glasgow Coma Scale, tachypnea, CT or MRI scan or fundoscopic evidence of cerebral edema, and/or of gray matter and white matter damage. Plasma ammonia, plasma amino acid (including plasma glutamine), blood glucose, serum electrolytes (sodium, potassium, chloride, or bicarbonate), hepatic and renal function tests, blood pH and pCO<sub>2</sub>, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, memory impairment); infusion site.</p></div>
<div class="block rerp drugH1Div" id="F53568726"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Long-term target levels (may not be appropriate for every patient) (Häberle 2019); refer to institutional protocols or consult with metabolic specialist:</p>
<p style="text-indent:-2em;margin-left:2em;">Plasma ammonia: &lt;80 μmol/L.</p>
<p style="text-indent:-2em;margin-left:2em;">Plasma glutamine: &lt;1,000 μmol/L.</p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: High normal range.</p>
<p style="text-indent:-2em;margin-left:2em;">Essential and branch chain amino acids: Normal range.</p></div>
<div class="block pha drugH1Div" id="F221894"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sodium phenylacetate and sodium benzoate provide alternate pathways for the removal of ammonia in patients with decreased or deficient enzymes in the urea cycle, which when functioning properly, forms water-soluble conjugation products that can be excreted in the urine. Sodium phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, while sodium benzoate conjugates with glycine to form hippuric acid and is excreted by the kidneys. One mole of phenylacetate removes 2 moles of nitrogen and 1 mole of benzoate removes 1 mole of nitrogen (Häberle 2012; Husson 2016).</p></div>
<div class="block phk drugH1Div" id="F221910"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic and renal; sodium phenylacetate conjugates with glutamine, forming the active metabolite, phenylacetylglutamine (PAG); sodium benzoate combines with glycine to form the active metabolite hippuric acid (HIP) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine</p></div>
<div class="block phksp drugH1Div" id="F51221393"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: Bioavailability of phenylacetate and benzoate was slightly higher in women than men; however, conclusion cannot be drawn because of the small number of subjects in the study.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58197800"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ammonul</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ammonul</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sodium phenylacetate and sodium benzoate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ammonul</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ammonul</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ammonul</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Ammonul (sodium phenylacetate and sodium benzoate) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BIMDG.1">
<a name="BIMDG.1"></a>British Inherited Metabolic Disease Group (BIMDG). Management of a baby at risk of a urea cycle disorder at birth. https://www.bimdg.org.uk/store/guidelines/UCD-at-birthrev51-288975-22-05-2013.pdf. Reviewed April 2017. Accessed April 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17538087">
<a name="17538087"></a>Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. <i>N Engl J Med</i>. 2007;356(22):2282-2292. doi:10.1056/NEJMoa066596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/17538087/pubmed" id="17538087" target="_blank">17538087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7847413">
<a name="7847413"></a>Gutteridge C, Kuhn RJ. Compatibility of 10% Sodium Benzoate Plus 10% Sodium Phenylacetate With Various Flavored Vehicles. <i>Am J Hosp Pharm</i>. 1994;51(19):2508, 2510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/7847413/pubmed" id="7847413" target="_blank">7847413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22642880">
<a name="22642880"></a>Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. <i>Orphanet J Rare Dis</i>. 2012;7:32. doi:10.1186/1750-1172-7-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/22642880/pubmed" id="22642880" target="_blank">22642880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982989">
<a name="30982989"></a>Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. <i>J Inherit Metab Dis</i>. 2019;42(6):1192-1230. doi:10.1002/jimd.12100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/30982989/pubmed" id="30982989" target="_blank">30982989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663197">
<a name="27663197"></a>Husson MC, Schiff M, Fouilhoux A, et al. Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study. <i>Orphanet J Rare Dis</i>. 2016;11(1):127. doi:10.1186/s13023-016-0513-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/27663197/pubmed" id="27663197" target="_blank">27663197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148544">
<a name="11148544"></a>Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1)(suppl):S6-S10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148544/pubmed" id="11148544" target="_blank">11148544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148503">
<a name="11148503"></a>Urea Cycle Disorders (UCD) Conference Group. Consensus Statement From a Conference for the Management of Patients With Urea Cycle Disorders. <i>J Pediatr</i>. 2001;138(1)(suppl):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/11148503/pubmed" id="11148503" target="_blank">11148503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29396029">
<a name="29396029"></a>Wilnai Y, Blumenfeld YJ, Cusmano K, et al. Prenatal treatment of ornithine transcarbamylase deficiency. <i>Mol Genet Metab</i>. 2018;123(3):297-300. doi:10.1016/j.ymgme.2018.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-phenylacetate-and-sodium-benzoate-pediatric-drug-information/abstract-text/29396029/pubmed" id="29396029" target="_blank">29396029</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12951 Version 102.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
